88 Chapter 6 Table 3. Validation cohort Baseline characteristics of the validation cohort and stratified for implant loss. Baseline characteristics No implant loss (n=3462) Implant loss (n=307) P-value* Age, years 48.7 ± 11.4 50.3 ± 10.3 0.007 BMI, L2/m 24.6 ± 4.2 25.6 ± 4.7 <0.001 Obesity 356 (10.3) 45 (11.2) 0.017 ASA score 0.112 I 1775 (51.7) 144 (47.4) II 1512 (44.0) 140 (46.1) III 149 (4.3) 20 (6.6) Missing 26 3 Current smoker 425 (12.3) 61 (19.9) <0.001 Indication 0.081 Breast cancer 2803 (81.0) 261 (85.0) Prophylactic 659 (19.0) 46 (15.0) Neoadjuvant radiotherapy 155 (4.5) 24 (7.8) 0.009 Missing 19 0 Preoperative antibiotics 3341 (96.8) 297 (97.1) 0.794 Missing 10 1 Antiseptic rinse 3169 (91.9) 273 (88.9) 0.070 Missing 14 0 Kellerfunnel 329 (9.6) 33 (10.7) 0.495 Missing 17 0 Nippleguards 1001 (29.0) 85 (27.7) 0.617 Missing 15 0 Type reconstruction 0.912 Permanent implant 765 (22.1) 67 (21.8) Tissue expander 2697 (77.9) 240 (78.2) Nipple preserving 1034 (29.9) 92 (30.0) 0.971 PM cover 3134 (91.1) 264 (86.3) 0.001 Missing 21 1 Mastopexy 69 (2.0) 9 (2.9) 0.271 Missing 20 1 Drains 3304 (95.5) 293 (95.4) 0.949
RkJQdWJsaXNoZXIy MTk4NDMw